TAP Submits New Drug Application for Febuxostat for Hyperuricemia in Chronic Gout
Apr 5th 2007Drug InformationGout
OSAKA, JAPAN — Takeda Pharmaceutical Company Limited (”Takeda”) announced today that TAP Pharmaceutical Products Inc (”TAP”), its 50-50 joint venture with Abbott Laboratories, submitted a New Drug Application (”NDA”) on December 14 with the US Food and Drug Administration for febuxostat 80mg and 120mg for the management of hyperuricemia in patients with chronic gout. [click link for full article]
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
